Cipher Pharmaceuticals has acquired worldwide rights to three products from Astion Pharma, a Denmark-based specialty pharma company. The three products are focused on inflammatory dermatological diseases: Dermadexin, Pruridexin, and ASF-1096.   Astion will receive an upfront payment of $6.0 million, and a subsequent $2.5 million upon regulatory approval and commercialization of Dermadexin or Pruridexin in the U.S. Additionally, the agreement includes approximately $31.5 million in payments based...